Recently presented data has shown that there is a clinical improvement in median radiologic progression-free survival (rPFS) when olaparib (Lynparza) is used in combination with abiraterone (ZYTIGA) compared to abiraterone alone in men with metastatic castration-resistant prostate cancer (mCRPC).
The data came from Study 08, a randomized, double-blinded, multicenter phase II trial, comparing olaparib in combination with abiraterone (n=71) to abiraterone monotherapy (n=71) in patients with previously treated mCRPC, regardless of homologous recombination repair mutation status. These results were presented at the last American Society of Clinical Oncology (ASCO) annual meeting and were published in Lancet Oncology (2018; 19:975-86).The primary endpoint of the trial was rPFS.
Secondary endpoints included time to second progression or death, overall survival, and health-related quality of life. Median rPFS was 13.8 months with olaparib and abiraterone compared to 8.2 months with abiraterone alone. Median time to second progression or death was 23.3 months versus 18.5 months. Median overall survival was 22.7 months with combination treatment versus 20.9 months with abiraterone alone.
This trial was small and needs to be repeated in a larger phase III trial. However, this information should be discussed with your doctors if you are taking Zytiga,
Joel T. Nowak, MA, MSW wrote this Post. Joel is the CEO/Executive Director of Cancer ABCs. He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and the rare cancer Appendiceal cancer.
